<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084825</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365625</org_study_id>
    <secondary_id>MDA-ID-030222</secondary_id>
    <secondary_id>MSKCC-03149</secondary_id>
    <secondary_id>ID03-0222</secondary_id>
    <nct_id>NCT00084825</nct_id>
  </id_info>
  <brief_title>Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008</brief_title>
  <official_title>Crossover From Docetaxel and Placebo to Docetaxel and Imatinib in Patients With Androgen-Independent Prostate Cancer With Bone Metastases: Extension Trial to ID03-0008</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of&#xD;
      tumor cells by blocking the enzymes necessary for their growth. Giving docetaxel with&#xD;
      imatinib mesylate may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel with imatinib mesylate&#xD;
      works in treating patients with androgen-independent prostate cancer and bone metastases that&#xD;
      progressed while receiving docetaxel and a placebo on clinical trial MDA-ID-030008.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Provide treatment with docetaxel and imatinib mesylate for patients with&#xD;
           androgen-independent prostate cancer and bone metastases that progressed while receiving&#xD;
           docetaxel and placebo on MDA-ID-030008.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate and time to progression in these patients after crossover&#xD;
           from docetaxel and placebo to docetaxel and imatinib mesylate.&#xD;
&#xD;
        -  Compare the modulation of the platelet-derived growth factor receptor pathway by&#xD;
           docetaxel and imatinib mesylate vs docetaxel and placebo in the same patient.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this crossover regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, crossover, multicenter, extension study. Patients who&#xD;
      progressed on the placebo and docetaxel arm of MDA-ID-030008 crossover to receive docetaxel&#xD;
      and imatinib mesylate.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate&#xD;
      once daily on days 1-42. Courses repeat every 42 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, before each therapy course, and at the completion of&#xD;
      therapy.&#xD;
&#xD;
      Patients are followed for 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>12 weeks after initiation of crossover therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From registration to disease progression, up to 32 months</time_frame>
    <description>Time of progression was defined as the time of appearance of symptoms attributable to disease progression, the first demonstrated clinical sign or radiological evidence of disease progression, or the time of first of consecutive prostate-specific antigen (PSA) increments that achieved 25% increase over baseline or nadir (or death during the study), whichever was earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Imatinib Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>30 mg/m^2 IV on days 1, 8, 15, and 22 every 42 days</description>
    <arm_group_label>Docetaxel + Imatinib Mesylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate</intervention_name>
    <description>600 mg orally daily</description>
    <arm_group_label>Docetaxel + Imatinib Mesylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
               -  Osseous metastases&#xD;
&#xD;
          -  Androgen-independent disease&#xD;
&#xD;
          -  Previously randomized to the docetaxel and placebo arm of protocol MDA-ID-030008 and&#xD;
             has been removed from protocol due to disease progression&#xD;
&#xD;
               -  No more than 6 weeks since final treatment with docetaxel and placebo&#xD;
&#xD;
          -  No uncontrolled brain metastases or spinal cord compression&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2 times upper limit&#xD;
             of normal&#xD;
&#xD;
          -  No chronic liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled severe hypertension&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No oxygen-dependent lung disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior dose-limiting toxicity with docetaxel requiring more than 2 dose reductions&#xD;
&#xD;
          -  No severe hypersensitivity to docetaxel&#xD;
&#xD;
          -  No prior dose-limiting toxicity with docetaxel requiring 1 dose reduction AND&#xD;
             experienced recurrent grade 3 or 4 toxicity at the time of progression on&#xD;
             MDA-ID-030008&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No concurrent severe infection&#xD;
&#xD;
          -  No overt psychosis, mental disability, or other incompetency that would preclude&#xD;
             giving informed consent&#xD;
&#xD;
          -  No history of non-compliance&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent second-line hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No recent strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent therapeutic warfarin&#xD;
&#xD;
               -  Concurrent mini-dose warfarin (1 mg/day) for central venous catheter prophylaxis&#xD;
                  allowed&#xD;
&#xD;
          -  No concurrent grapefruit or grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Mathew</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Logothetis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Official Website</description>
  </link>
  <results_reference>
    <citation>Mathew P, Thall PF, Johnson MM, et al.: Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). [Abstract] J Clin Oncol 24 (Suppl 18): A-4562, 232s, 2006.</citation>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

